Chai-3 Model Adopted by BMS and Pharma Giants for Drug Discovery
saranormous · x · 2026-08-20
- Partnership: Chai Discovery announced BMS will use its models to support new therapeutics discovery. Previous partners include Eli Lilly, Novartis, Pfizer, and argenx.
- Model Capabilities: Since rolling out Chai-3 earlier this year, leading biopharma companies have adopted the models. The company states that the latest model generations are critical in distinguishing successful molecule discovery.
- Industry View: Chai Discovery emphasizes that scientific discovery is the domain where access to frontier AI matters most, with their models playing a substantial role in the process.
More from Companies & People
- Accenture caps Claude reimbursement at $29/month, employees used to $1,000 scramble — _rchaves_ · 2026-10-16
- AI billboards take to the LA skies as startup hires plane to tow ad banner — TarlonKhoubyari · 2026-10-16
- SUNY Albany to offer Topological Deep Learning course, from Perceptrons to WL test — burny_tech · 2026-10-16
- Palantir opens third year of merit-only Meritocracy Fellowship applications — eliano · 2026-10-16
- Why hiring 'technical people who can create content' is so hard, from a Cerebras dev — charles_irl · 2026-10-16
- Sentry to host System Update panel on agentic coding with OpenAI, Linear, DoorDash leaders — zeeg · 2026-10-16